|
US3152180A
(en)
|
1960-08-25 |
1964-10-06 |
Studiengesellschaft Kohle Mbh |
Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines
|
|
US3391142A
(en)
|
1966-02-09 |
1968-07-02 |
Lilly Co Eli |
Adamantyl secondary amines
|
|
GB1173492A
(en)
|
1966-02-18 |
1969-12-10 |
Upjohn Co |
Acylamino-Adamantane Derivatives
|
|
FR2219159A1
(en)
|
1973-02-23 |
1974-09-20 |
Commissariat Energie Atomique |
Adamantane nitroxide radicals - antiviral and anticancer agents, also useful in nuclear resonance magnetometry
|
|
US3992518A
(en)
|
1974-10-24 |
1976-11-16 |
G. D. Searle & Co. |
Method for making a microsealed delivery device
|
|
US4284444A
(en)
|
1977-08-01 |
1981-08-18 |
Herculite Protective Fabrics Corporation |
Activated polymer materials and process for making same
|
|
US4148896A
(en)
|
1978-02-22 |
1979-04-10 |
E. I. Du Pont De Nemours And Company |
Antidepressant combination
|
|
DE2856393C2
(de)
|
1978-12-27 |
1983-04-28 |
Merz + Co GmbH & Co, 6000 Frankfurt |
Arzneimittel zur Behandlung von Morbus Parkinson
|
|
IE52535B1
(en)
*
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
EP0064646B1
(en)
|
1981-04-24 |
1991-02-27 |
E.R. Squibb & Sons, Inc. |
Use for the manufacture of oral forms of nadolol for treating glaucoma
|
|
US4346112A
(en)
|
1981-06-29 |
1982-08-24 |
University Patents Inc. |
Composition and method for treating patients having Parkinson's Disease
|
|
JPS584718A
(ja)
|
1981-06-30 |
1983-01-11 |
Nippon Chibagaigii Kk |
新規適応症に用うる医薬製剤
|
|
DK150008C
(da)
|
1981-11-20 |
1987-05-25 |
Benzon As Alfred |
Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
|
|
DE3581188D1
(de)
|
1984-07-24 |
1991-02-07 |
Key Pharma |
Klebende schicht zur transdermalen freigabe.
|
|
US4769027A
(en)
|
1984-08-15 |
1988-09-06 |
Burroughs Wellcome Co. |
Delivery system
|
|
IL74497A
(en)
|
1985-03-05 |
1990-02-09 |
Proterra Ag |
Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
|
|
IT1188212B
(it)
|
1985-12-20 |
1988-01-07 |
Paolo Colombo |
Sistema per il rilascio a velocita' controllata di sostanze attive
|
|
US4663318A
(en)
|
1986-01-15 |
1987-05-05 |
Bonnie Davis |
Method of treating Alzheimer's disease
|
|
EP0241809B1
(de)
|
1986-04-16 |
1990-08-08 |
ASTA Pharma Aktiengesellschaft |
Synergistische Kombination von Amantadin und Selegilin
|
|
FI95572C
(fi)
|
1987-06-22 |
1996-02-26 |
Eisai Co Ltd |
Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
|
|
US4897268A
(en)
|
1987-08-03 |
1990-01-30 |
Southern Research Institute |
Drug delivery system and method of making the same
|
|
US4861800A
(en)
|
1987-08-18 |
1989-08-29 |
Buyske Donald A |
Method for administering the drug deprenyl so as to minimize the danger of side effects
|
|
US4878913A
(en)
*
|
1987-09-04 |
1989-11-07 |
Pfizer Hospital Products Group, Inc. |
Devices for neural signal transmission
|
|
US4904681A
(en)
|
1987-12-01 |
1990-02-27 |
G. D. Searle & Co. |
D-cycloserine and its prodrugs as cognitive enhancers
|
|
GB8807504D0
(en)
|
1988-03-29 |
1988-05-05 |
Sandoz Ltd |
Improvements in/relating to organic compounds
|
|
US5422120A
(en)
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
|
US5061721A
(en)
|
1989-03-15 |
1991-10-29 |
G. D. Searle & Co. |
Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
|
|
US5334618A
(en)
|
1991-04-04 |
1994-08-02 |
The Children's Medical Center Corporation |
Method of preventing NMDA receptor-mediated neuronal damage
|
|
DE10299048I2
(de)
|
1989-04-14 |
2006-07-13 |
Merz Pharma Gmbh & Co Kgaa |
Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
|
|
WO1991006291A1
(fr)
|
1989-10-26 |
1991-05-16 |
Nippon Shinyaku Co., Ltd. |
Preparation a liberation entretenue
|
|
SG88714A1
(en)
|
1989-11-06 |
2002-05-21 |
Cell Genesys Inc |
Production of proteins using homologous recombination
|
|
IT1237904B
(it)
|
1989-12-14 |
1993-06-18 |
Ubaldo Conte |
Compresse a rilascio a velocita' controllata delle sostanze attive
|
|
CA2037178A1
(en)
|
1990-02-28 |
1991-08-29 |
Albert Walter Brzeczko |
Deprenyl/l-dopa/carbidopa pharmaceutical composition
|
|
ZA911974B
(en)
|
1990-03-21 |
1994-08-22 |
Res Dev Foundation |
Heterovesicular liposomes
|
|
US5190763A
(en)
|
1990-05-07 |
1993-03-02 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
|
US5192550A
(en)
|
1990-05-07 |
1993-03-09 |
Alza Corporation |
Dosage form for treating central nervous system disorders
|
|
US5221536A
(en)
|
1990-05-07 |
1993-06-22 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
|
US5057321A
(en)
|
1990-06-13 |
1991-10-15 |
Alza Corporation |
Dosage form comprising drug and maltodextrin
|
|
US5086072A
(en)
|
1990-06-18 |
1992-02-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
|
|
IN172468B
(enExample)
|
1990-07-14 |
1993-08-14 |
Asta Medica Ag |
|
|
EP0488959A3
(en)
|
1990-11-28 |
1992-08-05 |
Sandoz Ltd. |
New uses of competitive nmda receptor antagonists
|
|
GB9104854D0
(en)
|
1991-03-07 |
1991-04-17 |
Reckitt & Colmann Prod Ltd |
Sustained release compositions
|
|
US5614560A
(en)
|
1991-04-04 |
1997-03-25 |
Children's Medical Center Corporation |
Method of preventing NMDA receptor-mediated neuronal damage
|
|
US5455279A
(en)
|
1991-04-19 |
1995-10-03 |
The Children's Medical Center Corporation |
Regimen method of mediating neuronal damage using nitroglycerine
|
|
US6764697B1
(en)
|
1991-06-27 |
2004-07-20 |
Alza Corporation |
System for delaying drug delivery up to seven hours
|
|
US5326570A
(en)
|
1991-07-23 |
1994-07-05 |
Pharmavene, Inc. |
Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
|
|
KR100221695B1
(ko)
|
1991-08-12 |
1999-09-15 |
그린 마틴, 브라이언 쥐 테슬리 |
약학적 구상 제형
|
|
DE4225730C2
(de)
*
|
1992-08-04 |
2003-04-30 |
Merz Pharma Gmbh & Co Kgaa |
Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
|
|
DE4236752A1
(de)
|
1992-10-30 |
1994-05-05 |
Asta Medica Ag |
Kombinationspräparat aus Flupirtin und Morphin zur Behandlung von Schmerzen und zur Vermeidung der Morphin-Abhängigkeit
|
|
US5358721A
(en)
|
1992-12-04 |
1994-10-25 |
Alza Corporation |
Antiviral therapy
|
|
CA2115792C
(en)
|
1993-03-05 |
2005-11-01 |
David J. Mayer |
Method for the treatment of pain
|
|
US5648087A
(en)
|
1993-03-09 |
1997-07-15 |
Sanofi Sante Nutrition Animale |
Anaesthetic pharmaceutical composition comprising a general anaesthetic and selegiline
|
|
AU676315B2
(en)
|
1993-06-30 |
1997-03-06 |
Takeda Chemical Industries Ltd. |
Stabilized solid pharmaceutical preparation and method of producing the same
|
|
EP0711166A1
(en)
*
|
1993-07-22 |
1996-05-15 |
Warner-Lambert Company |
Controlled release tacrine drug delivery systems and methods for preparing same
|
|
US6908910B2
(en)
|
1993-08-06 |
2005-06-21 |
The Children's Medical Center Corporation |
Estrogenic compounds as anti-mitotic agents
|
|
HUT75162A
(en)
|
1993-11-16 |
1997-04-28 |
Depotech Corp |
Vesicles with controlled release of actives
|
|
US5395626A
(en)
|
1994-03-23 |
1995-03-07 |
Ortho Pharmaceutical Corporation |
Multilayered controlled release pharmaceutical dosage form
|
|
US5484608A
(en)
|
1994-03-28 |
1996-01-16 |
Pharmavene, Inc. |
Sustained-release drug delivery system
|
|
US5660848A
(en)
|
1994-11-02 |
1997-08-26 |
The Population Council, Center For Biomedical Research |
Subdermally implantable device
|
|
US20020006438A1
(en)
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
|
DE19510189A1
(de)
|
1995-03-21 |
1996-09-26 |
Hartmut Dr Goebel |
Verwendung von Amantadin
|
|
US5677349A
(en)
|
1995-04-27 |
1997-10-14 |
Gilad; Gad M. |
Agmatine for the treatment of neurotrauma and neurodegenerative diseases
|
|
DK0828513T3
(da)
|
1995-05-26 |
2004-04-13 |
Pfizer |
Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
|
|
DE19528388A1
(de)
|
1995-08-02 |
1997-02-06 |
Hans Peter Prof Dr Med Zenner |
Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
|
|
AUPN605795A0
(en)
|
1995-10-19 |
1995-11-09 |
F.H. Faulding & Co. Limited |
Analgesic pharmaceutical composition
|
|
US6095148A
(en)
*
|
1995-11-03 |
2000-08-01 |
Children's Medical Center Corporation |
Neuronal stimulation using electrically conducting polymers
|
|
US6395292B2
(en)
|
1996-02-02 |
2002-05-28 |
Alza Corporation |
Sustained delivery of an active agent using an implantable system
|
|
DE69733081T2
(de)
|
1996-08-23 |
2006-05-11 |
Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) |
Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
|
|
US5958919A
(en)
|
1996-09-20 |
1999-09-28 |
Washington University |
Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
|
|
US5891885A
(en)
|
1996-10-09 |
1999-04-06 |
Algos Pharmaceutical Corporation |
Method for treating migraine
|
|
US5919826A
(en)
|
1996-10-24 |
1999-07-06 |
Algos Pharmaceutical Corporation |
Method of alleviating pain
|
|
ATE314054T1
(de)
|
1996-10-25 |
2006-01-15 |
Shire Lab Inc |
Osmotisches verabreichungssystem für lösliche dosen
|
|
DE19644998C1
(de)
|
1996-10-30 |
1998-06-10 |
Hanns Prof Dr Ludwig |
Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier
|
|
US6919373B1
(en)
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
|
JPH10203966A
(ja)
|
1996-11-21 |
1998-08-04 |
Takeda Chem Ind Ltd |
徐放性マイクロカプセルおよびその製造法
|
|
AU736308B2
(en)
|
1996-12-20 |
2001-07-26 |
Warner-Lambert Company Llc |
Antitussive drugs delivered by ion exchange resins
|
|
USRE39744E1
(en)
|
1997-03-11 |
2007-07-24 |
Daicel Chemical Industries, Ltd. |
Adamantane derivatives and process for producing them
|
|
DE69805909T2
(de)
|
1997-04-10 |
2002-09-26 |
Pfizer Inc., New York |
Fluorosubstituierte Adamantan-Derivate
|
|
CA2289190A1
(en)
|
1997-05-07 |
1998-11-12 |
Algos Pharmaceutical Corporation |
Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
|
|
MY125849A
(en)
|
1997-07-25 |
2006-08-30 |
Alza Corp |
Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
|
|
MA26553A1
(fr)
|
1997-10-17 |
2004-12-20 |
Centaur Pharmaceuticals Inc |
Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
|
|
US6391922B1
(en)
|
1998-01-13 |
2002-05-21 |
Synchroneuron, Llc |
Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
|
|
US6007841A
(en)
*
|
1998-03-13 |
1999-12-28 |
Algos Pharmaceutical Corporation |
Analgesic composition and method for treating pain
|
|
DE19834764A1
(de)
*
|
1998-08-01 |
2000-02-03 |
Univ Hannover |
Mittel zur Stabilisierung von Lebensmitteln und kosmetischen Mitteln sowie Verfahren zu dessen Herstellung
|
|
SK287111B6
(sk)
|
1998-08-27 |
2009-12-07 |
Pharmacia & Upjohn Ab |
Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
|
|
DE69915346T2
(de)
|
1998-12-17 |
2004-07-22 |
Alza Corp., Mountain View |
Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
|
|
US6797283B1
(en)
|
1998-12-23 |
2004-09-28 |
Alza Corporation |
Gastric retention dosage form having multiple layers
|
|
US8545880B2
(en)
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
|
US6248363B1
(en)
*
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
NZ514442A
(en)
|
1999-03-03 |
2003-08-29 |
Optinose As |
Nasal delivery device
|
|
SE9901077D0
(sv)
|
1999-03-23 |
1999-03-23 |
Astra Ab |
Novel use
|
|
US6183770B1
(en)
|
1999-04-15 |
2001-02-06 |
Acutek International |
Carrier patch for the delivery of agents to the skin
|
|
US6743211B1
(en)
|
1999-11-23 |
2004-06-01 |
Georgia Tech Research Corporation |
Devices and methods for enhanced microneedle penetration of biological barriers
|
|
JP2003509439A
(ja)
|
1999-09-14 |
2003-03-11 |
スミスクライン・ビーチャム・コーポレイション |
水性コーティングされたビーズレットの製法
|
|
EP2295043A1
(en)
|
1999-10-29 |
2011-03-16 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
|
WO2001032115A1
(en)
*
|
1999-11-04 |
2001-05-10 |
Xel Herbaceuticals |
Transdermal administration of huperzine
|
|
AU2084801A
(en)
|
1999-12-09 |
2001-06-18 |
Alza Corporation |
Antiviral medication
|
|
CA2394980C
(en)
|
1999-12-22 |
2008-05-13 |
Shearwater Corporation |
Sterically hindered derivatives of water soluble polymers
|
|
US6491949B2
(en)
|
2000-01-14 |
2002-12-10 |
Osmotica Corp. |
Osmotic device within an osmotic device
|
|
US6444702B1
(en)
*
|
2000-02-22 |
2002-09-03 |
Neuromolecular, Inc. |
Aminoadamantane derivatives as therapeutic agents
|
|
US6455066B1
(en)
|
2000-03-10 |
2002-09-24 |
Epicept Corporation |
Intradermal-penetration agents for topical local anesthetic administration
|
|
EP1559418A1
(en)
|
2000-06-26 |
2005-08-03 |
EpiCept Corporation |
Compositions for treating pain of the mucous membrane
|
|
US6648083B2
(en)
|
2000-11-02 |
2003-11-18 |
Schlumberger Technology Corporation |
Method and apparatus for measuring mud and formation properties downhole
|
|
US20040122090A1
(en)
|
2001-12-07 |
2004-06-24 |
Lipton Stuart A. |
Methods for treating neuropsychiatric disorders with nmda receptor antagonists
|
|
CN1527813A
(zh)
|
2001-04-02 |
2004-09-08 |
О |
作为治疗剂的抗氧化剂硝基氧和亚硝氮碳基
|
|
DE10129265A1
(de)
|
2001-06-18 |
2003-01-02 |
Hf Arzneimittelforsch Gmbh |
Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
|
|
US6500454B1
(en)
|
2001-10-04 |
2002-12-31 |
Eurand Pharmaceuticals Ltd. |
Timed, sustained release systems for propranolol
|
|
PT1485078E
(pt)
|
2002-03-15 |
2013-01-14 |
Cypress Bioscience Inc |
Milnacipran para o tratamento do síndrome do intestino irritável
|
|
IL149055A0
(en)
|
2002-04-09 |
2002-11-10 |
Karma Pharm Ltd |
Extended release composition comprising as active compound venlafaxine hydrochloride
|
|
TW531966B
(en)
*
|
2002-05-20 |
2003-05-11 |
Mediatek Inc |
Phase lock loop with low static state phase error and calibration circuit
|
|
US20040102525A1
(en)
|
2002-05-22 |
2004-05-27 |
Kozachuk Walter E. |
Compositions and methods of treating neurological disease and providing neuroprotection
|
|
EP1509232B1
(en)
|
2002-05-31 |
2008-11-19 |
H. Lundbeck A/S |
A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
|
|
US6662845B1
(en)
|
2002-06-19 |
2003-12-16 |
Newell Operating Company |
Roman shade with separated backing sheet
|
|
US6945952B2
(en)
|
2002-06-25 |
2005-09-20 |
Theraject, Inc. |
Solid solution perforator for drug delivery and other applications
|
|
WO2004002565A1
(en)
|
2002-06-26 |
2004-01-08 |
Alza Corporation |
Minimally compliant, volume efficient piston for osmotic drug delivery systems
|
|
US20050208132A1
(en)
|
2002-07-29 |
2005-09-22 |
Gayatri Sathyan |
Methods and dosage forms for reducing side effects of benzisozazole derivatives
|
|
DK1524981T3
(da)
*
|
2002-07-29 |
2009-06-22 |
Glaxo Group Ltd |
Sammensætninger med vedvarende frigivelse indeholdende lamotrigin
|
|
US7985422B2
(en)
*
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
US6913768B2
(en)
|
2002-09-24 |
2005-07-05 |
Shire Laboratories, Inc. |
Sustained release delivery of amphetamine salts
|
|
US20050075679A1
(en)
*
|
2002-09-30 |
2005-04-07 |
Gliner Bradford E. |
Methods and apparatuses for treating neurological disorders by electrically stimulating cells implanted in the nervous system
|
|
CN100339070C
(zh)
*
|
2002-10-24 |
2007-09-26 |
莫茨药物股份两合公司 |
包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
|
|
CN1726012A
(zh)
*
|
2002-12-11 |
2006-01-25 |
辉瑞产品公司 |
活性物质在高脂肪环境中的控制释放
|
|
US20040224020A1
(en)
|
2002-12-18 |
2004-11-11 |
Schoenhard Grant L. |
Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
|
|
WO2004056335A2
(es)
|
2002-12-23 |
2004-07-08 |
Osmotica Costa Rica Sociedad Anonima |
Dispositivo de liberación que contiene venlafaxina y memantina
|
|
US20050031651A1
(en)
|
2002-12-24 |
2005-02-10 |
Francine Gervais |
Therapeutic formulations for the treatment of beta-amyloid related diseases
|
|
ES2214129B1
(es)
*
|
2003-02-13 |
2005-12-01 |
Almirall Prodesfarma, S.A. |
3-fenilfuran-2-onas.
|
|
AR043467A1
(es)
|
2003-03-05 |
2005-07-27 |
Osmotica Argentina S A |
Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
|
|
US20050065219A1
(en)
|
2003-03-27 |
2005-03-24 |
Lipton Stuart A. |
Treatment of demyelinating conditions
|
|
CA2525195A1
(en)
*
|
2003-05-09 |
2004-11-18 |
Pharmacia & Upjohn Company Llc |
Pyrazinones as crf1 receptor antagonists for the treatment of cns disorders
|
|
WO2005019166A2
(en)
|
2003-06-11 |
2005-03-03 |
Neuromolecular, Inc. |
Method of targeting a therapeutic agent
|
|
BRPI0411451A
(pt)
|
2003-06-16 |
2006-07-18 |
Allergan Inc |
formas de dosagens orais de memantina
|
|
US20060079578A1
(en)
*
|
2003-06-23 |
2006-04-13 |
Julie Laurin |
Pharmaceutical formulations of amyloid inhibiting compounds
|
|
KR100524018B1
(ko)
|
2003-07-25 |
2005-10-26 |
삼성전자주식회사 |
이동형 디스플레이장치 및 이동형 디스플레이 시스템
|
|
US20050037364A1
(en)
*
|
2003-08-13 |
2005-02-17 |
International Business Machines Corporation |
Techniques for recording signals
|
|
AU2004316119B2
(en)
|
2003-10-22 |
2008-04-24 |
Merz Pharma Gmbh & Co. Kgaa |
The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic AB peptides in amyloidopathies
|
|
AU2004292966A1
(en)
|
2003-11-21 |
2005-06-09 |
Memory Pharmaceutical Corporation |
Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors
|
|
US20050119249A1
(en)
*
|
2003-12-02 |
2005-06-02 |
Erik Buntinx |
Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
|
|
US7553858B2
(en)
|
2003-12-17 |
2009-06-30 |
Meda Pharma Gmbh & Co. Kg |
Combination of flupirtine and tramadol
|
|
WO2005065645A2
(en)
*
|
2003-12-31 |
2005-07-21 |
Actavis Group Hf |
Donepezil formulations
|
|
US20050191349A1
(en)
*
|
2003-12-31 |
2005-09-01 |
Garth Boehm |
Galantamine formulations
|
|
SI1703902T1
(sl)
|
2004-01-05 |
2011-02-28 |
Merz Pharma Gmbh & Co Kgaa |
Memantin za zdravljenje blage do zmerne Alzheimerjeve bolezni
|
|
EP1715843A1
(en)
|
2004-01-29 |
2006-11-02 |
Neuromolecular Inc. |
Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
|
|
EP1727538A2
(en)
|
2004-02-13 |
2006-12-06 |
Neuromolecular Inc. |
Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
|
|
WO2005079756A2
(en)
|
2004-02-13 |
2005-09-01 |
Neuromolecular, Inc. |
Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
|
|
ATE454140T1
(de)
|
2004-02-18 |
2010-01-15 |
Sepracor Inc |
Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
|
|
TW200531680A
(en)
*
|
2004-03-03 |
2005-10-01 |
Merz Pharma Gmbh & Co Kgaa |
Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
|
|
JP2007529556A
(ja)
|
2004-03-19 |
2007-10-25 |
アクソニクス インコーポレイテッド |
認知障害の処置に有用なアセチルコリンエステラーゼ阻害剤およびｎ−メチル−ｄ−アスパラギン酸拮抗剤
|
|
US20060002999A1
(en)
|
2004-06-17 |
2006-01-05 |
Forest Laboratories, Inc. |
Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
|
|
WO2006009769A1
(en)
|
2004-06-17 |
2006-01-26 |
Forest Laboratories, Inc. |
Modified release formulation of memantine
|
|
US7346382B2
(en)
*
|
2004-07-07 |
2008-03-18 |
The Cleveland Clinic Foundation |
Brain stimulation models, systems, devices, and methods
|
|
WO2006024018A2
(en)
|
2004-08-24 |
2006-03-02 |
Neuromolecular Pharmaceuticals, Inc. |
Compositions for treating nociceptive pain
|
|
WO2006042249A2
(en)
|
2004-10-08 |
2006-04-20 |
Neuromolecular Pharmaceuticals, Inc. |
Methods and compositions for treating migraine pain
|
|
US8058291B2
(en)
|
2005-04-06 |
2011-11-15 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for the treatment of CNS-related conditions
|
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
|
EP2623099A1
(en)
|
2004-11-24 |
2013-08-07 |
Neuromolecular Pharmaceuticals, Inc |
Composition and method for treating neurological disease
|
|
AR053986A1
(es)
|
2004-12-03 |
2007-05-30 |
Osmotica Pharmaceutical Argent |
Dispositivo osmotico que contiene amantadina y una sal osmotica
|
|
US8252331B2
(en)
|
2004-12-03 |
2012-08-28 |
Osmotica Kereskedelmi és Szolgáltató, KFT |
Osmotic device containing amantadine and an osmotic salt
|
|
US20060160852A1
(en)
|
2004-12-27 |
2006-07-20 |
Eisai Co. Ltd. |
Composition containing anti-dementia drug
|
|
US20060246003A1
(en)
*
|
2004-12-27 |
2006-11-02 |
Eisai Co. Ltd. |
Composition containing anti-dementia drug
|
|
US20090208579A1
(en)
|
2004-12-27 |
2009-08-20 |
Eisai R & D Management Co., Ltd. |
Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
|
|
US20080279819A1
(en)
|
2005-02-15 |
2008-11-13 |
Adamas Pharmaceuticals, Inc. |
Combinations Therapy for Treatment of Demyelinating Conditions
|
|
EA013474B1
(ru)
|
2005-06-16 |
2010-04-30 |
Форест Лэборэтериз, Инк. |
Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
|
|
EP1977746B8
(en)
|
2007-04-02 |
2014-09-24 |
Parkinson's Institute |
Methods and compositions for reduction of side effects of therapeutic treatments
|